精神分裂症的糖生物学:基因组研究引出的生物学假说
该综述基于精神分裂症GWAS证据,提出糖基化在疾病发生中可能起关键作用。作者指出最强的编码变异位于锰转运体SLC39A8,与人类糖基化模式改变相关;多个编码糖基化酶的基因附近变异与精神分裂症明确关联,包括FUT9、MAN2A1、TMTC1、GALNT10和B3GAT1。作者假设常见遗传变异改变脑内糖基化并在精神分裂症发展中起基础性作用。
要点
- 精神分裂症GWAS中最强编码变异为SLC39A8错义突变,与人类糖基化模式改变相关。
- FUT9、MAN2A1、TMTC1、GALNT10和B3GAT1附近变异与精神分裂症明确关联。
- 谷氨酸受体、电压门控钙通道、多巴胺D2受体和补体糖蛋白受糖基化关键修饰。
核心结论
- 常见遗传变异可能通过改变脑内糖基化参与精神分裂症发生。
- 糖基化是精神分裂症基因组研究中浮现但未被充分重视的生物学主题。
研究设计与样本
- 综述类文章,围绕精神分裂症GWAS发现的糖基化相关基因与通路进行整合与假说提出。
主要发现
- 精神分裂症GWAS中最强编码变异为锰转运体SLC39A8错义突变,该突变与人类糖基化模式改变相关。
- FUT9、MAN2A1、TMTC1、GALNT10和B3GAT1等编码糖基化酶的基因附近变异与精神分裂症明确关联。
- 谷氨酸受体、电压门控钙通道、多巴胺D2受体和补体糖蛋白等精神分裂症相关蛋白受糖基化关键修饰。
关键数值与推荐
- 文中未报告具体效应量、阈值或推荐条款。
临床怎么用
- 提示临床与基础研究可关注糖基化通路作为精神分裂症机制探索与治疗开发的新方向。
- 强调SLC39A8及糖基化酶基因可作为后续功能研究的候选靶点。
局限性
- 本文为假说性综述,未提供原始实验数据验证糖基化改变与精神分裂症的因果关系。
- 原文未系统报告各基因变异的效应大小或人群归因风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Advances in genomics are opening new windows into the biology of schizophrenia. Though common variants individually have small effects on disease risk, GWAS provide a powerful opportunity to explore pathways and mechanisms contributing to pathophysiology. Here, we highlight an underappreciated biological theme emerging from GWAS: the role of glycosylation in schizophrenia. The strongest coding variant in schizophrenia GWAS is a missense mutation in the manganese transporter SLC39A8, which is associated with altered glycosylation patterns in humans. Furthermore, variants near several genes encoding glycosylation enzymes are unambiguously associated with schizophrenia: FUT9, MAN2A1, TMTC1, GALNT10, and B3GAT1. Here, we summarize the known biological functions, target substrates, and expression patterns of these enzymes as a primer for future studies. We also highlight a subset of schizophrenia-associated proteins critically modified by glycosylation including glutamate receptors, voltage-gated calcium channels, the dopamine D2 receptor, and complement glycoproteins. We hypothesize that common genetic variants alter brain glycosylation and play a fundamental role in the development of schizophrenia. Leveraging these findings will advance our mechanistic understanding of disease and may provide novel avenues for treatment development.
引用
- Mealer RG, Williams SE, Daly MJ, et al. Glycobiology and schizophrenia: a biological hypothesis emerging from genomic research. Mol Psychiatry. 2020. PMID: 32377000. doi:10.1038/s41380-020-0753-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。